Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma

CONCLUSIONS: Our results suggest that post-nephrectomy RCC patients with sarcomatoid differentiation and high PD-L1 expression were more responsive to ICIs. Furthermore, pembrolizumab monotherapy exhibited superior DFS and OS results over other adjuvant therapies.PMID:38494564 | DOI:10.1245/s10434-024-15121-2

Source: Ann Oncol - March 18, 2024 Category: Cancer & Oncology Authors: Kaiyue Ding Zhixuan Yang Danyan Zhang Lin Sun Source Type: research